Generation of Human Induced Pluripotent Stem Cell‐Derived Bona Fide Neural Stem Cells for Ex Vivo Gene Therapy of Metachromatic Leukodystrophy

Allogeneic fetal‐derived human neural stem cells (hfNSCs) that are under clinical evaluation for several neurodegenerative diseases display a favorable safety profile, but require immunosuppression upon transplantation in patients. Neural progenitors derived from patient‐specific induced pluripotent stem cells (iPSCs) may be relevant for autologous ex vivo gene‐therapy applications to treat genetic diseases with unmet medical need. In this scenario, obtaining iPSC‐derived neural stem cells (NSCs) showing a reliable “NSC signature” is mandatory. Here, we generated human iPSC (hiPSC) clones via reprogramming of skin fibroblasts derived from normal donors and patients affected by metachromatic leukodystrophy (MLD), a fatal neurodegenerative lysosomal storage disease caused by genetic defects of the arylsulfatase A (ARSA) enzyme. We differentiated hiPSCs into NSCs (hiPS‐NSCs) sharing molecular, phenotypic, and functional identity with hfNSCs, which we used as a “gold standard” in a side‐by‐side comparison when validating the phenotype of hiPS‐NSCs and predicting their performance after intracerebral transplantation. Using lentiviral vectors, we efficiently transduced MLD hiPSCs, achieving supraphysiological ARSA activity that further increased upon neural differentiation. Intracerebral transplantation of hiPS‐NSCs into neonatal and adult immunodeficient MLD mice stably restored ARSA activity in the whole central nervous system. Importantly, we observed a significant decrease of sulfatide storage when ARSA‐overexpressing cells were used, with a clear advantage in those mice receiving neonatal as compared with adult intervention. Thus, we generated a renewable source of ARSA‐overexpressing iPSC‐derived bona fide hNSCs with improved features compared with clinically approved hfNSCs. Patient‐specific ARSA‐overexpressing hiPS‐NSCs may be used in autologous ex vivo gene therapy protocols to provide long‐lasting enzymatic supply in MLD‐affected brains. Stem Cells Translational Medicine 2017;6:352–368

[1]  P. Rancoita,et al.  Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial , 2016, The Lancet.

[2]  D. Peterson,et al.  Pluripotent stem cell‐derived radial glia‐like cells as stable intermediate for efficient generation of human oligodendrocytes , 2015, Glia.

[3]  G. Ming,et al.  Adult Mammalian Neural Stem Cells and Neurogenesis: Five Decades Later. , 2015, Cell stem cell.

[4]  O. Brüstle,et al.  Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  V. Fossati,et al.  Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells , 2015, Nature Protocols.

[6]  J. Wolfe,et al.  Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model , 2015, Stem cell reports.

[7]  A. Ricca,et al.  Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy , 2015, Human molecular genetics.

[8]  J. Glass,et al.  Human neural stem cell transplantation in ALS: initial results from a phase I trial , 2015, Journal of Translational Medicine.

[9]  S. Pluchino,et al.  Neuro-immune interactions of neural stem cell transplants: From animal disease models to human trials , 2014, Experimental Neurology.

[10]  M. Araúzo-Bravo,et al.  Origin-dependent neural cell identities in differentiated human iPSCs in vitro and after transplantation into the mouse brain. , 2014, Cell reports.

[11]  H. Schöler,et al.  Induced Neural Stem Cells Achieve Long-Term Survival and Functional Integration in the Adult Mouse Brain , 2014, Stem cell reports.

[12]  A. Gritti,et al.  Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy , 2014, Human molecular genetics.

[13]  G. Pan,et al.  Neural progenitor cells from human induced pluripotent stem cells generated less autogenous immune response , 2014, Science China Life Sciences.

[14]  S. Pluchino,et al.  How stem cells speak with host immune cells in inflammatory brain diseases , 2013, Glia.

[15]  A. Tsukamoto,et al.  Clinical translation of human neural stem cells , 2013, Stem Cell Research & Therapy.

[16]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[17]  Daniel J. Guillaume,et al.  Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. , 2013, Journal of neurosurgery. Pediatrics.

[18]  M. Poe,et al.  Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Yan Liu,et al.  Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. , 2013, Cell reports.

[20]  T. Nägele,et al.  Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort , 2013, Bone Marrow Transplantation.

[21]  K. Hochedlinger,et al.  Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. , 2013, Cell stem cell.

[22]  Brian J Cummings,et al.  Human neural stem cells induce functional myelination in mice with severe dysmyelination (Science Translational Medicine (2012) 4, (165er7)) , 2012 .

[23]  M. Mcglynn.  StemCells, Inc.: Clinical trials of stem cell therapies for CNS disorders. Interview with Martin McGlynn. , 2012, Regenerative medicine.

[24]  Brian J Cummings,et al.  Human Neural Stem Cells Induce Functional Myelination in Mice with Severe Dysmyelination , 2012, Science Translational Medicine.

[25]  O. Lindvall,et al.  Cross-talk between neural stem cells and immune cells: the key to better brain repair? , 2012, Nature Neuroscience.

[26]  G. Martino,et al.  Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. , 2012, Current opinion in neurology.

[27]  S. Pluchino,et al.  Extracellular Membrane Vesicles and Immune Regulation in the Brain , 2012, Front. Physio..

[28]  Matthew Trotter,et al.  Capture of Neuroepithelial-Like Stem Cells from Pluripotent Stem Cells Provides a Versatile System for In Vitro Production of Human Neurons , 2012, PloS one.

[29]  Michal Schwartz,et al.  Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells. , 2011, Physiological reviews.

[30]  R. Jaenisch,et al.  Transgene Excision Has No Impact on In Vivo Integration of Human iPS Derived Neural Precursors , 2011, PloS one.

[31]  S. Blanchard,et al.  Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. , 2011, Human molecular genetics.

[32]  M. Neri,et al.  Neural Stem Cell Gene Therapy Ameliorates Pathology and Function in a Mouse Model of Globoid Cell Leukodystrophy , 2011, Stem cells.

[33]  P G Pelicci,et al.  Genomic instability in induced stem cells , 2011, Cell Death and Differentiation.

[34]  M. Kabra,et al.  Molecular and structural analysis of metachromatic leukodystrophy patients in Indian population , 2011, Journal of the Neurological Sciences.

[35]  Beau R. Webber,et al.  Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). , 2011, Blood.

[36]  Alessandra Biffi,et al.  Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy , 2010, Science Translational Medicine.

[37]  P. Menéndez,et al.  iPSC lines that do not silence the expression of the ectopic reprogramming factors may display enhanced propensity to genomic instability , 2010, Cell Research.

[38]  Margherita Neri,et al.  Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. , 2010, Human molecular genetics.

[39]  V. Broccoli,et al.  Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors. , 2010, Experimental cell research.

[40]  M. Neri,et al.  Robust Generation of Oligodendrocyte Progenitors from Human Neural Stem Cells and Engraftment in Experimental Demyelination Models in Mice , 2010, PloS one.

[41]  Elena Cattaneo,et al.  Neural stem cell systems: physiological players or in vitro entities? , 2010, Nature Reviews Neuroscience.

[42]  Chad A. Cowan,et al.  Genome modification in human embryonic stem cells , 2010, Journal of cellular physiology.

[43]  I. Weissman,et al.  Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. , 2009, Cell stem cell.

[44]  G. Comi,et al.  Human neural stem cells ameliorate autoimmune encephalomyelitis in non‐human primates , 2009, Annals of neurology.

[45]  E. Snyder,et al.  Neural Stem Cell Transplantation Benefits a Monogenic Neurometabolic Disorder During the Symptomatic Phase of Disease , 2009, Stem cells.

[46]  G. Comi,et al.  Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. , 2009, Brain : a journal of neurology.

[47]  J. Bonifacino,et al.  Sorting of lysosomal proteins. , 2009, Biochimica et biophysica acta.

[48]  O. Brüstle,et al.  A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration , 2009, Proceedings of the National Academy of Sciences.

[49]  E. Bongarzone,et al.  Multipotential Neural Precursors Transplanted into the Metachromatic Leukodystrophy Brain Fail to Generate Oligodendrocytes but Contribute to Limit Brain Dysfunction , 2008, Developmental Neuroscience.

[50]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[51]  M. Haskins,et al.  CNS‐directed gene therapy for lysosomal storage diseases , 2008, Acta paediatrica.

[52]  Yechiel Elkabetz,et al.  Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. , 2008, Genes & development.

[53]  George Q. Daley,et al.  Reprogramming of human somatic cells to pluripotency with defined factors , 2008, Nature.

[54]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[55]  T. Graf.  Faculty Opinions recommendation of Induction of pluripotent stem cells from adult human fibroblasts by defined factors. , 2007 .

[56]  S. Yamanaka.  Strategies and new developments in the generation of patient-specific pluripotent stem cells. , 2007, Cell stem cell.

[57]  S. Lipton,et al.  Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease , 2007, Nature Medicine.

[58]  Seung U. Kim,et al.  Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and Functional Recovery in Mouse Stroke Model , 2007, PloS one.

[59]  R. Sidman,et al.  Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non‐autonomous disorders: evidence from a mouse model of Krabbe leukodystrophy , 2006, Journal of neurochemistry.

[60]  Atul Mehta,et al.  Lysosomal Storage Disorders , 2005 .

[61]  L. Naldini,et al.  Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters , 2005, Nature Biotechnology.

[62]  R. Lüllmann-Rauch,et al.  Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution , 2004, Acta Neuropathologica.

[63]  L. Naldini,et al.  Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. , 2004, The Journal of clinical investigation.

[64]  Y. Ioannou,et al.  Gene therapy for lysosomal storage disorders , 2003, Expert opinion on biological therapy.

[65]  I. Weissman,et al.  Direct isolation of human central nervous system stem cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  E. Parati,et al.  Isolation and Cloning of Multipotential Stem Cells from the Embryonic Human CNS and Establishment of Transplantable Human Neural Stem Cell Lines by Epigenetic Stimulation , 1999, Experimental Neurology.

[67]  R. D'Hooge,et al.  Metachromatic leukodystrophy: Molecular genetics and an animal model , 1998, Journal of Inherited Metabolic Disease.

[68]  G. Lukatela,et al.  Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. , 1998, Biochemistry.

[69]  K. von Figura,et al.  Glycosylation and phosphorylation of arylsulfatase A. , 1994, The Journal of biological chemistry.

[70]  A. Tylki-Szymańska,et al.  Homozygote for mutation c.1204 + 1G > A of the ARSA gene presents with a late-infantile form of metachromatic leukodystrophy and a rare MRI white matter lesion type. , 2005, Journal of applied genetics.

[71]  K. von Figura,et al.  Genetics of metachromatic leukodystrophy. , 1994, Gene therapy.

[72]  N. Baumann,et al.  P-Nitrocatechol sulfate for arylsulfatase assay: detection of metachromatic leukodystrophy variants. , 1976, Advances in experimental medicine and biology.